NEC Baby Formula Settlement Amounts: There Is a $70 Million Verdict, Not a Settlement
In April 2026, a jury in Chicago awarded four families a combined $70 million after finding that cow's milk-based infant formula contributed to their premature infants' necrotizing enterocolitis (NEC). That was a jury verdict in one trial, not a settlement, and it can still be reduced or overturned on appeal. The consolidated federal litigation, MDL 3026, has not reached a global settlement, and a separate bellwether trial began on 6 July 2026 to test how the next case is evaluated. This page explains what is actually known, and why there is no settlement amount to report.
Editorially Reviewed — Content reviewed for accuracy using published legal research, government data, and verified court records. See our methodology
Reviewed by Leonard Goldberg, Editor · Last updated
What the NEC Baby Formula Lawsuits Allege
The lawsuits consolidated in MDL 3026 involve families of premature infants who allege that cow's milk-based formula products -- primarily Similac, made by Abbott, and Enfamil, made by Mead Johnson -- increased the risk of necrotizing enterocolitis (NEC), a serious and often fatal intestinal disease that disproportionately affects premature and low-birth-weight infants. The claims center on allegations that the manufacturers did not adequately warn hospitals and parents about this risk for premature infants specifically. As of August 2026, 825 active lawsuits are pending in the consolidated litigation before Judge Rebecca Pallmeyer in the Northern District of Illinois.
Case Details
MDL 3026, In re: Similac, Enfamil, and Other Infant Formula Products Liability Litigation, United States District Court for the Northern District of Illinois, before Judge Rebecca Pallmeyer. 825 active lawsuits pending as of August 2026.
Where the Litigation Stands Today
One jury verdict, one bellwether trial underway, no global settlement. In April 2026, a Chicago jury heard evidence in a trial involving four families and awarded a combined $70 million, with individual family awards ranging from $7 million to $16 million. That is a verdict reached by a jury in a specific trial -- it is not a settlement, and it does not set a payout amount for any other case. Verdicts in cases like this can be, and often are, reduced by the trial judge or on appeal, and a defendant can appeal a verdict entirely, which can take years to resolve before any money changes hands.
On 6 July 2026, a separate case became the first federally coordinated bellwether trial in MDL 3026. The plaintiff, Alexis Inman, alleges that Enfamil cow's milk-based formula contributed to the death of her infant son, Daniel Inman, from necrotizing enterocolitis. A bellwether trial is a case selected from the larger pool of consolidated lawsuits to be tried first, so that both sides -- and the judge overseeing the litigation -- can see how a jury evaluates the evidence common to many of the cases. Its outcome is not binding on the other 825 pending cases, but it commonly shapes how both sides approach settlement talks for the litigation as a whole. No outcome of that trial had been reported at the time this page was prepared, and none is predicted here.
There is no global settlement in MDL 3026. No settlement fund exists, no claim form has been published, and no deadline has been set for infant formula NEC claims generally. What exists is one completed jury trial with a verdict under possible appeal, and one bellwether trial in progress.
Who These Lawsuits Involve
The lawsuits consolidated in MDL 3026 generally involve families of infants who were born prematurely, were fed cow's milk-based formula (such as Similac or Enfamil) rather than human milk or a human-milk-based product, and subsequently developed necrotizing enterocolitis. Because there is no confirmed settlement or trust, there is no published eligibility checklist to compare a case against -- eligibility in litigation like this is ultimately determined case by case, based on medical records and the specific facts of the exposure.
What is worth doing now, independent of how the litigation develops:
- Preserve medical records. NICU records documenting the formula used, the diagnosis, and treatment are central to any claim of this kind, and become harder to obtain the longer they wait.
- Understand that a verdict in one case is not money available in another. The $70 million verdict belongs to the four families in that specific trial. It does not create a fund that other families can apply to.
- Be skeptical of anyone offering to file a claim against a settlement that does not exist. As of this writing, MDL 3026 has not settled.
What the $70 Million Verdict Does and Doesn't Tell You
The April 2026 verdict is the largest publicly known figure connected to this litigation, and it is worth being precise about what it is and isn't.
What it is: a jury's award to four specific families in one specific trial, based on the evidence presented in that case. The per-family amounts, ranging from $7 million to $16 million, reflect the jury's assessment of those four families' individual circumstances -- not a formula that applies to other cases.
What it is not: a settlement amount, a floor for future verdicts, or a ceiling. Jury verdicts of this size are routinely appealed, and appellate courts can reduce them substantially, send them back for a new trial, or in some cases eliminate them entirely. Until any appeal in that case is resolved, the $70 million figure is not final. It also is not a signal about what a bellwether trial or a future settlement might produce -- juries in different trials, hearing different evidence about different infants, can and do reach very different conclusions.
Advertising or intake calls that treat $70 million, or the $7 million-to-$16 million range, as an indication of what a NEC baby formula claim is 'worth' are extrapolating from a single trial to a litigation that has not settled. There is currently no verified settlement amount, average payout, or per-claim estimate for MDL 3026 as a whole, and this page will not manufacture one.
How the Litigation Has Developed
- 1
MDL 3026 is established
Lawsuits alleging that cow's milk-based infant formula, including Similac and Enfamil, increased the risk of necrotizing enterocolitis in premature infants are consolidated into MDL 3026 before Judge Rebecca Pallmeyer in the Northern District of Illinois, for coordinated pretrial proceedings.
- 2
Active case count grows to 825
As of August 2026, 825 lawsuits are active in the consolidated litigation, brought by families of infants who developed necrotizing enterocolitis after being fed cow's milk-based formula.
- 3
April 2026 — a Chicago jury returns a $70 million verdict
A jury hearing a trial involving four families awards a combined $70 million, with individual family awards ranging from $7 million to $16 million. This is a verdict in one trial, reached by one jury, and is subject to post-trial motions and possible appeal.
- 4
The verdict is not the end of that case
A jury verdict of this size is routinely challenged after trial. It can be reduced by the trial judge, appealed by the defendant, and either upheld, reduced, or overturned by an appellate court — a process that can take years before any of the awarded amount is actually paid.
- 5
6 July 2026 — the first federal bellwether trial begins
The first bellwether trial coordinated through MDL 3026 begins. The plaintiff, Alexis Inman, alleges that Enfamil cow's milk-based formula contributed to the fatal necrotizing enterocolitis of her infant son, Daniel Inman.
- 6
What the bellwether trial is testing
A bellwether trial is a case selected from the larger pool of consolidated lawsuits to go to trial first, so both sides can see how a jury weighs the evidence that many of the 825 pending cases share. Its result does not bind the other cases, but it typically informs how both plaintiffs and defendants approach the litigation going forward, including any eventual settlement discussions.
- 7
Current status: no global settlement
As of this page's preparation, MDL 3026 has not reached a global settlement. One jury verdict exists (under the possibility of appeal), one bellwether trial has begun, and 825 cases remain active without a resolved outcome.
What to Be Careful About
A large jury verdict connected to infant illness and death draws attention, and with it, offers that get ahead of what has actually happened. These are the patterns worth being cautious about with this specific litigation.
"File a claim against the $70 million settlement"
The $70 million is a jury verdict awarded to four specific families in one trial, not a settlement fund that other families can file a claim against. There is no NEC baby formula settlement fund, no claims administrator, and no claim form for MDL 3026 as a whole. Anyone describing the $70 million as a pool to apply to is describing something that does not exist.
Quoting the $7 million–$16 million range as a typical payout
Those figures reflect what one jury awarded to four particular families based on the specific facts of their case. They are not an average, a minimum, or a predictor of what any other family's case might be worth. A litigation that has not settled has no verified average settlement amount.
Treating the bellwether trial's outcome as decided
The first federal bellwether trial in MDL 3026 began 6 July 2026 and its outcome should not be presented as known, predicted, or as setting a new payout figure, before it has concluded and been reported. Be cautious of anyone citing a specific result from this trial as though it were already final.
Common Questions
Has the NEC baby formula lawsuit settled?
No. As of this page's preparation, MDL 3026, the consolidated federal litigation over cow's milk-based infant formula and necrotizing enterocolitis, has not reached a global settlement. There is a $70 million jury verdict from one trial in April 2026, and a separate bellwether trial that began 6 July 2026, but no settlement fund, claim form, or deadline exists for the litigation as a whole.
What was the $70 million verdict for?
In April 2026, a jury in Chicago awarded a combined $70 million to four families in a single trial, with individual family awards ranging from $7 million to $16 million, after finding that cow's milk-based formula contributed to their infants' necrotizing enterocolitis. It is a verdict in one case, not a settlement covering other cases, and it can still be reduced or overturned on appeal.
Can the $70 million verdict be appealed or reduced?
Yes. Jury verdicts of this size are commonly challenged through post-trial motions and appeal. A trial judge can reduce the amount, and an appellate court can uphold, reduce, or overturn the verdict entirely. Until that process concludes, the $70 million is not a final, guaranteed payment.
What is the bellwether trial that started in July 2026?
On 6 July 2026, the first federal bellwether trial in MDL 3026 began. The plaintiff, Alexis Inman, alleges that Enfamil cow's milk-based formula contributed to the fatal necrotizing enterocolitis of her son, Daniel Inman. A bellwether trial is a representative case tried first from a larger pool of consolidated lawsuits, so both sides can gauge how a jury evaluates shared evidence — its outcome does not bind the other 825 pending cases but often shapes settlement discussions.
How many NEC baby formula lawsuits are pending?
As of August 2026, 825 active lawsuits are pending in MDL 3026 before Judge Rebecca Pallmeyer in the U.S. District Court for the Northern District of Illinois.
Is there a settlement amount I can expect for a NEC baby formula claim?
No verified settlement amount exists, because MDL 3026 has not settled. The $70 million verdict and its $7 million-to-$16 million per-family breakdown describe what one jury awarded in one trial; they are not an average, minimum, or estimate for any other case.
Which companies are named in the NEC baby formula lawsuits?
The consolidated litigation primarily involves cow's milk-based infant formula products, including Similac, made by Abbott, and Enfamil, made by Mead Johnson. The claims allege that the manufacturers did not adequately warn about the elevated NEC risk for premature infants specifically.
What should someone with a potential NEC baby formula claim do now?
Preserve NICU and medical records documenting the formula used, the NEC diagnosis, and the infant's treatment — these become harder to obtain over time and are central to any claim, whether it proceeds through the existing MDL, a future bellwether trial, or eventual settlement discussions. There is no settlement claim to file at this stage, because none exists yet.
Separate from this case: were you injured in the last 2 years?
Class-action payouts are fixed amounts through an administrator. A personal injury claim is a different case — and often worth far more. Free estimate, no obligation.